The FDA has not approved a stem-cell or exosome therapy specifically for erectile dysfunction as a licensed product. Investigational MSC protocols are registered with the NIH but remain unapproved for this indication. The EMA likewise has not granted a marketed ED-specific stem-cell product. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) remain the FDA-approved first-line pharmacological treatment. Patients should distinguish investigational stem-cell protocols from unproven direct-to-consumer ED clinics, which proliferate globally and often lack regulatory oversight.
Erectile dysfunction (ED) arises from vascular insufficiency, endothelial dysfunction, smooth-muscle pathology, or neurogenic impairment — often clustering with metabolic syndrome, atherosclerosis, and diabetes. Stem-cell investigations focus on whether placental mesenchymal stem cells and exosome preparations can regenerate penile vasculature, restore endothelial nitric-oxide-dependent relaxation, and repair cavernous smooth-muscle tissue. With 35 registered trials and 5 currently recruiting, the biological rationale targets restoration of penile erectile mechanics through vascular and tissue regeneration. Early clinical data suggest potential for improving erectile function, increasing rigidity and tumescence duration, and potentially reducing pharmacological dependence on phosphodiesterase-5 inhibitors when stem-cell therapy complements standard medical management.
Am I a candidate? → · Erectile Dysfunction: full overview → · Erectile Dysfunction cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية